Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from InnoCare Pharma Ltd. ( (HK:9969) ).
InnoCare Pharma Ltd. has appointed Prof. Kunliang Guan as an independent non-executive director, effective January 21, 2025. Prof. Guan, a highly distinguished researcher in molecular biology and genetics, is expected to bring valuable expertise to the company. His appointment is part of the company’s strategic efforts to strengthen its board with experienced professionals to enhance its research capabilities and industry position.
More about InnoCare Pharma Ltd.
InnoCare Pharma Ltd. is a pharmaceutical company operating in the biotech industry, primarily focusing on the research and development of treatments for cancer and autoimmune diseases. The company is listed on the Hong Kong Stock Exchange and is dedicated to developing innovative therapies.
YTD Price Performance: -7.84%
Average Trading Volume: 4,606,587
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$8.44B
Learn more about 9969 stock on TipRanks’ Stock Analysis page.
